和铂医药-B（HBM HOLDINGS-B）宣布，公司符合资格获得总额最高达11亿美元的额外开发、监管及商业里程碑付款。
这一重大财务前景基于公司现有合作协议的条款，反映出其研发管线与商业合作的强劲潜力。
里程碑付款将分阶段兑现，具体与候选药物的临床进展、监管审批以及最终商业化成果紧密挂钩。
和铂医药-B（HBM HOLDINGS-B）宣布，公司符合资格获得总额最高达11亿美元的额外开发、监管及商业里程碑付款。
这一重大财务前景基于公司现有合作协议的条款，反映出其研发管线与商业合作的强劲潜力。
里程碑付款将分阶段兑现，具体与候选药物的临床进展、监管审批以及最终商业化成果紧密挂钩。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.